Kodiak Sciences advances late-stage studies with KSI-301 in vision loss disorders

• Kodiak Sciences (NASDAQ:KOD) has announced that the first patients have been treated in three Phase 3 studies of KSI-301, an anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM and GLIMMER studies) and macular edema due to retinal vein occlusion (BEACON study).
• Additional Phase 1b study data showed, treatment-naïve patients, after three loading doses, 72% of Wet age-related macular degeneration (wAMD) and 79% of diabetic macular edema patients have achieved a six-month or longer treatment free interval at least once during follow-up. In Retinal Vein Occlusion, 81% of patients achieved a four-month or longer treatment free interval at least once during follow-up.
• Patient recruitment in U.S. for DAZZLE Phase 2b/3 study of KSI-301 in treatment-naïve wAMD is complete, though in Europe is ongoing, and Kodiak expects to complete DAZZLE enrollment this year.
• The company expects to submit KSI-301 marketing application in 2022.
• https://seekingalpha.com/news/3619804-kodiak-sciences-advances-late-stage-studies-ksiminus-301-in-vision-loss-disorders